Universal Flu Vaccine Enters Phase III with Broad Protection
Single-dose vaccine targeting conserved proteins provides protection against all known flu strains.
1Universal Approach
A universal influenza vaccine that targets highly conserved regions of the hemagglutinin stalk has entered Phase III clinical trials after demonstrating broad protection against all known influenza A and B strains in earlier-phase studies .
2Phase III Design
The vaccine, developed by the NIH Vaccine Research Center, uses a nanoparticle platform that presents the conserved stalk domain in a way that elicits broadly neutralizing antibodies . In Phase II trials involving 3,200 participants, a single dose provided protection against 18 of 18 tested influenza subtypes.
3Broad-Spectrum Results
Current seasonal flu vaccines must be reformulated annually based on predictions about which strains will circulate, and their effectiveness varies from 10-60% depending on the match . A universal vaccine would eliminate this guesswork and provide consistent, reliable protection.
4Public Health Impact
The Phase III trial will enroll 12,000 participants across 45 sites globally, with results expected in 18 months. If successful, it would represent the most significant advance in influenza prevention since the development of the first flu vaccine in 1945 .
- Protection against all 18 tested influenza subtypes
- Single-dose nanoparticle platform
- Targets conserved hemagglutinin stalk domain
- Phase III enrolling 12,000 across 45 global sites
- Could replace annual seasonal flu vaccination
Dive Deeper into the Research
Switch to PhD Mode to explore the underlying papers, knowledge graph connections, pathway analyses, and collaborate with researchers working on Influenza.
In This Article
Related Conditions
Active Clinical Trials
Phase III: Immunology Study
Recruiting at 12 sites nationwide
Related Articles
Researcher Interest
7,845 consumers have expressed interest in this topic. Researchers studying Influenza can see anonymized demand signals.
Universal Flu Vaccine Enters Phase III with Broad Protection
Single-dose vaccine targeting conserved proteins provides protection against all known flu strains.
1Universal Approach
A universal influenza vaccine that targets highly conserved regions of the hemagglutinin stalk has entered Phase III clinical trials after demonstrating broad protection against all known influenza A and B strains in earlier-phase studies .
2Phase III Design
The vaccine, developed by the NIH Vaccine Research Center, uses a nanoparticle platform that presents the conserved stalk domain in a way that elicits broadly neutralizing antibodies . In Phase II trials involving 3,200 participants, a single dose provided protection against 18 of 18 tested influenza subtypes.
3Broad-Spectrum Results
Current seasonal flu vaccines must be reformulated annually based on predictions about which strains will circulate, and their effectiveness varies from 10-60% depending on the match . A universal vaccine would eliminate this guesswork and provide consistent, reliable protection.
4Public Health Impact
The Phase III trial will enroll 12,000 participants across 45 sites globally, with results expected in 18 months. If successful, it would represent the most significant advance in influenza prevention since the development of the first flu vaccine in 1945 .
- Protection against all 18 tested influenza subtypes
- Single-dose nanoparticle platform
- Targets conserved hemagglutinin stalk domain
- Phase III enrolling 12,000 across 45 global sites
- Could replace annual seasonal flu vaccination
Dive Deeper into the Research
Switch to PhD Mode to explore the underlying papers, knowledge graph connections, pathway analyses, and collaborate with researchers working on Influenza.
In This Article
Related Conditions
Active Clinical Trials
Phase III: Immunology Study
Recruiting at 12 sites nationwide
Related Articles
Researcher Interest
7,845 consumers have expressed interest in this topic. Researchers studying Influenza can see anonymized demand signals.